-
On the journey to combat cancer, the medical community has been constantly seeking more effective and safer treatment methods. While surgery, radiotherapy, chemotherapy, and biotherapy have laid a solid foundation for cancer treatment, hyperthermia—a modern technology derived from ancient wisdom—...Read more »
-
Facing a cancer diagnosis, the shared hope of patients worldwide is to find the most effective, advanced, and minimally invasive treatment option. If you are looking for a hospital that combines top-tier Chinese medical expertise, cutting-edge technology, and internationally standard services, th...Read more »
-
When you or a loved one faces a cancer diagnosis and feels limited or hopeless while seeking treatment options locally, do you ever wonder: On the other side of the world, are there more advanced, less invasive, and more hopeful treatment options available? For inquiries about new cancer therapie...Read more »
-
A terminal brain cancer patient, who had relapsed after 17 CAR-T treatments, saw his tumor completely disappear within 4 weeks of receiving a novel TIL therapy and has remained tumor-free for over 20 months. For inquiries about new cancer therapies and clinical trials: Phone: 4008803716 | WeChat:...Read more »
-
November 17, 2025,Abbisko announced the poster presentation of longer-term efficacy, safety and patient-reported outcomes from the global Phase III MANEUVER study of pimicotinib (ABSK021) in patients with tenosynovial giant cell tumour (TGCT) at the Connective Tissue Oncology Society (CTOS) 2025 ...Read more »
-
Sept. 8, 2025， InnoCare Pharma announced that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL). At present, there are still many clinical trials of new an...Read more »
-
On August 28, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that BL-B01D1 for injection is proposed to be included in the priority review process. It is intended for patients with recurrent or metastatic nasopharyngeal carcinoma who have pre...Read more »
-
August 21，bispecific T cell engager, epcoritamab, has been granted priority review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The approval is targeted at adult patients with relapsed or refractory follicular lymphoma (FL), a high need subset o...Read more »
-
August 29,Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has been approved as monotherapy by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have ...Read more »
-
On August 22, 2025, Datopotamab deruxtecan (Dato-DXd; Datroway) has received approval in China for the treatment of adult patients with unresectable or metastatic hormone receptor–positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization [ISH] negative) breast...Read more »
-
In August 2025, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) officially granted Breakthrough Therapy Designation to Ina-cel, a novel CD19-directed CAR-T cell therapy independently developed by Juventas, for the treatment of pediatric patients with re...Read more »
-
20 August 2025, Abbisko Therapeutics announced that the Center forDrug Evaluation (CDE) of the China National Medical Products Administration (NlPA) has cleared the lND application for Abbisko’sinvestigational oral PD-1 inhibitor, ABSK043, combined with Shanghai Alist Pharmaceuticals KRAS ...Read more »
Cooperative medical institution of
Beijing Cancer Hospital